Skip to main content
. Author manuscript; available in PMC: 2014 Nov 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2013 Sep 14;72(5):10.1007/s00280-013-2283-x. doi: 10.1007/s00280-013-2283-x

Fig 1.

Fig 1

Mean (±standard deviation) concentration versus time profile of nilotinib after p.o. administration of 400 mg nilotinib without calcium carbonate (●) and with calcium carbonate (○) in healthy volunteers.